Hemophilia A Gene Therapy
Jul 14, 2023
The Future is Here: BioMarin’s Roctavian First Hemophilia A Gene Therapy Paving the Way for a Cure
Hemophilia A is a rare genetic bleeding disorder that primarily affects males. Hemophilia A is the most common type of hemophilia, accounting for approximately 80% of all cases. It is estimated to occur in about 1 in 5,000 to 10,000 male births. As per the Centers for Disease Control (CDC) (2020), the estimated pre...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
